Gilead (NASDAQ: GILD) Beats Q1 Revenue Despite Stock Decline on Guidance Cut

Gilead Sciences Inc. (NASDAQ: GILD) beat first-quarter revenue expectations, yet the stock fell 1.64% to $134.06 after management revised full-year loss guidance and highlighted hefty acquisition integration costs, signaling near-term profitability pressure despite strong top-line performance.

Q1 2026 At a Glance

• Revenue growth: 4.7% year-over-year, driven by sustained HIV drug demand
• Gross margin: 78.84%, indicating strong pricing and product mix
• Operating margin: 37.38%, though pressure expected from acquisition costs
• Earnings growth: 23.4% year-over-year, yet overshadowed by full-year guidance reduction
• Profit margin: 28.9%, reflecting the company's pharma-scale profitability

What Drove the Results

Gilead's 4.7% revenue growth was anchored by its HIV antiviral franchise, which continues to command premium pricing and benefits from expanding treatment and prevention indications. The company's gross margin of 78.84% reflects the exceptional economics of HIV therapies, where branded medications face limited generic competition and reimbursement remains robust.

However, the headline beat masks operational headwinds. Management revised full-year guidance downward, citing substantial acquisition costs and integration expenses related to recent M&A activity. While the company did not detail the specific acquisitions in available reports, the guidance cut suggests these deals carry meaningful short-term dilution to earnings and operating margins—a red flag for investors expecting near-term profitability improvement.

The 23.4% earnings growth rate, while positive, is likely overstated by favorable comparisons to prior-year results; the guidance revision implies this growth will decelerate materially in subsequent quarters as acquisition costs mount.

Wall Street View

With a forward P/E of 13.94x versus a trailing 19.80x, the market has already repriced Gilead for a temporary earnings dip. Analysts appear to view the guidance cut as a one-time integration cost rather than a structural impairment of the business.

Investor Takeaway

Gilead's Q1 beat on revenue is offset by guidance reduction tied to acquisition integration. While the HIV franchise remains a cash cow with 78.84% gross margins, near-term profitability will suffer from M&A-related costs. The 13.94x forward P/E suggests the market expects earnings to recover post-integration, but investors should expect volatility through 2026 as the company works through acquisition synergies. Long-term holders of GILD should view the stock as a deep-value opportunity if acquisition integration executes on plan; near-term traders may face headwinds.